The Biomedical Advanced Research and Development Authority (BARDA) has recently awarded five indefinite delivery, indefinite quantity (IDIQ) contracts in support of the Medical Countermeasure Clinical Studies Network.
The goal of the network is to generate clinical trial data that will evaluate medical countermeasures, such as vaccines, therapeutics, diagnostics and medical devices.
The awardees will provide a full range of services including statistical expertise and project management, study design and protocol development, data collection, and data analysis and reporting. The two-year contracts, which includes three one-year options, each have a ceiling of $100 million and a minimum order guarantee of $400,000.
The following organizations were awarded the IDIQ contracts:
- Clinical Research Management, Inc.
- The EMMES Corporation
- PPD Development
- Rho Federal Systems Division, Inc.
- Technical Resources International, Inc.
Studies performed by this network will clinically evaluate Chemical, Biological, Radiological, Nuclear (CBRN), pandemic influenza and emerging infectious disease medical countermeasures. These studies may be Phase 1, 2, 3, or 4 or combinations of such.
Source: RFP-13-100-SOL-00008 (FBO.gov)
